OTC Markets OTCPK - Delayed Quote USD

Pharmagreen Biotech Inc. (PHBI)

0.0011
0.0000
(0.00%)
As of May 19 at 2:16:47 PM EDT. Market Open.
Loading Chart for PHBI
  • Previous Close 0.0011
  • Open 0.0011
  • Bid 0.0011 x --
  • Ask 0.0012 x --
  • Day's Range 0.0011 - 0.0011
  • 52 Week Range 0.0006 - 0.0047
  • Volume 219,973
  • Avg. Volume 1,144,629
  • Market Cap (intraday) 730,010
  • Beta (5Y Monthly) 1.78
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0000
  • Earnings Date Aug 11, 2025 - Aug 15, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Pharmagreen Biotech Inc. operates as a nutraceutical company, engages in the formulating products from blends of therapeutic plants and fungi in North America. The company's primary product is MaxGenomic supplement, a proprietary blend and formulated medicinal mushrooms and medical plants to support the human mind and body. It also provides consulting services for plant genetic selection, tissue culture technologies for starter plantlets production, SOPs for cultivation and live storage of any plant species services. It sells its products through online stores, such as Amazon and Shopify. Pharmagreen Biotech Inc. is headquartered in Coquitlam, Canada.

www.pharmagreen.ca

--

Full Time Employees

September 30

Fiscal Year Ends

Recent News: PHBI

View More

Performance Overview: PHBI

Trailing total returns as of 5/20/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

PHBI
26.67%
S&P 500 (^GSPC)
1.09%

1-Year Return

PHBI
83.33%
S&P 500 (^GSPC)
12.01%

3-Year Return

PHBI
87.78%
S&P 500 (^GSPC)
52.40%

5-Year Return

PHBI
97.76%
S&P 500 (^GSPC)
100.08%

Compare To: PHBI

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PHBI

View More

Valuation Measures

Annual
As of 5/19/2025
  • Market Cap

    730.01k

  • Enterprise Value

    1.12M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    327.15

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    720.63

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -139.13%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    3k

  • Net Income Avi to Common (ttm)

    -226.26k

  • Diluted EPS (ttm)

    -0.0000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    906

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -161.09k

Research Analysis: PHBI

View More

Company Insights: PHBI

Research Reports: PHBI

View More

People Also Watch